Patents Examined by Jeffrey S. Parkin
  • Patent number: 8088571
    Abstract: A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: January 3, 2012
    Assignees: Institut de Recherches Cliniques de Montreal, Institut National de la Recherche Scientifique
    Inventors: Nabil G. Seidah, Patrick Labonté
  • Patent number: 8088397
    Abstract: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: January 3, 2012
    Assignees: Hasumi, LLC, University of Maryland, Baltimore
    Inventors: Kenichiro Hasumi, Dean LeMar Mann, Kim Graulich Hankey, Kristina Michelle Holt
  • Patent number: 8088729
    Abstract: A method of inhibiting a viral infection of a host comprising administering to the host an anti-viral griffithsin polypeptide comprising SEQ ID NO: 3 or a fragment thereof comprising at least eight contiguous amino acids, a nucleic acid encoding the anti-viral polypeptide, or an antibody to the anti-viral polypeptide. A method of inhibiting a virus in a sample comprising contacting the sample with an anti-viral griffithsin polypeptide or antibody thereto also is provided.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 3, 2012
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Barry O'Keefe, Toshiyuki Mori, James B. McMahon
  • Patent number: 8080633
    Abstract: Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 20, 2011
    Inventors: Andrea Savarino, Umberto Dianzani
  • Patent number: 8080369
    Abstract: The present invention relates to methods to activate peripheral blood mononuclear cells. The present invention further provides methods for the identification of blocking agents of Tat protein activation of PBMCs and for identifying an active portion of a Tat polypeptide for incorporation as an immunogen in a vaccine. The present invention also provides an immunogen comprising an isolated variant of wild-type HIV Tat protein that exhibits reduced HIV priming of competent cells in comparison to the wild-type HIV Tat protein. The present invention further provides a diagnostic kit for identifying blocking agents for HIV Tat protein.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: December 20, 2011
    Assignee: The Board of Trustees of the Leland Standford Junior University
    Inventors: Lenore A. Herzenberg, Bita Sahaf
  • Patent number: 8076062
    Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: December 13, 2011
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Hilde Azijn, Marie-Pierre T. M. M. G De Bethune, Johan Hendrika Jozef Vingerhoets
  • Patent number: 8034350
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: October 11, 2011
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Sara Pagans Lista
  • Patent number: 8030444
    Abstract: Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 4, 2011
    Assignee: Jarrow Formulas, Inc.
    Inventors: Andrea Savarino, Umberto Dianzani
  • Patent number: 7988974
    Abstract: The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein, or fragments, analogs or homologs of DP178. The invention further relates to the uses of such fusion peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: August 2, 2011
    Assignee: Duke University
    Inventors: Michael L. Greenberg, Thomas James Matthews, Chin-Ho Chen
  • Patent number: 7951377
    Abstract: The present invention relates to mosaic clade M HIV-1 Env polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: May 31, 2011
    Assignees: Los Alamos National Security, LLC, Duke University, Beth Isreal Deaconess Medical Center, The University of Albama at Birmingham Research Foundation
    Inventors: Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
  • Patent number: 7947286
    Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: May 24, 2011
    Assignee: PanThera Biopharma LLC
    Inventors: Axel Thomas Lehrer, David Edward Clements, Tom Humphreys
  • Patent number: 7947807
    Abstract: An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: May 24, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Brian Kobilka, Dan Rohrer, Peter Brams, Asna Masood
  • Patent number: 7943146
    Abstract: The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: May 17, 2011
    Assignee: Myrexis, Inc.
    Inventors: Adrian Hobden, Kenton Zavitz, Scott Morham
  • Patent number: 7939083
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 10, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Antu K. Dey, John P. Moore, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Patent number: 7935797
    Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: May 3, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
  • Patent number: 7919101
    Abstract: Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: April 5, 2011
    Assignee: New York Blood Center
    Inventors: Shibo Jiang, Chungen Pan
  • Patent number: 7919100
    Abstract: The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size convenient for keeping the native conformation of the interaction between N- and C-helices, and —an hydrophily sufficient to provide a soluble and stable trimeric form to said modified polypeptide.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: April 5, 2011
    Assignee: Mymetics Corporation
    Inventors: Sylvain Fleury, Marc P Girard, Marie-Gaëlle Roger, Nicolas Mouz, Pierre-François Serres
  • Patent number: 7917303
    Abstract: Methods for identifying a motif or a combination of motifs having a Boolean state of predetermined mutations in a set of sequences including a) aligning a set of sequences of ordered motifs represented by a single-character code, b) comparing a reference sequence with the set of sequences aligned in step (a), c) identifying motifs not having mutated simultaneously and/or motifs having mutated simultaneously at least once on at least one sequence of the set and not having mutated on another sequence of the set.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 29, 2011
    Assignee: Centre National de la Recherche Scientifique—CNRS
    Inventors: Anne Vanet, Michaela Muller-Trutwin, Thomas Valère, Sophie Brouillet, Emmanuelle Ollivier, Laurent Marsan
  • Patent number: 7910716
    Abstract: Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: March 22, 2011
    Assignees: Medical Research Council, University of Cape Town Observatory, University of North Carolina at Chapel Hill, Alphavax, Incorporated
    Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
  • Patent number: 7901685
    Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: March 8, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon